학술논문
Low incidence and transient elevation of autoantibodies post mRNA COVID-19 vaccination in inflammatory arthritis.
Document Type
Article
Author
Blank, Rebecca B; Haberman, Rebecca H; Qian, Kun; Samanovic, Marie; Castillo, Rochelle; Hernandez, Anthony Jimenez; Girija, Parvathy Vasudevapillai; Catron, Sydney; Uddin, Zakwan; Rackoff, Paula; Solomon, Gary; Azar, Natalie; Rosenthal, Pamela; Izmirly, Peter; Samuels, Jonathan; Golden, Brian; Reddy, Soumya; Mulligan, Mark J; Hu, Jiyuan; Scher, Jose U
Source
Subject
*AUTOANTIBODIES
*IMMUNIZATION
*COVID-19 vaccines
*SERUM
*SEROCONVERSION
*DISEASE incidence
*COMPARATIVE studies
*TREATMENT effectiveness
*MESSENGER RNA
*RHEUMATOID arthritis
*ENZYME-linked immunosorbent assay
*DESCRIPTIVE statistics
*LONGITUDINAL method
*PHARMACODYNAMICS
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1462-0324
Abstract
Objectives Autoantibody seroconversion has been extensively studied in the context of COVID-19 infection but data regarding post-vaccination autoantibody production is lacking. Here we aimed to determine the incidence of common autoantibody formation following mRNA COVID-19 vaccines in patients with inflammatory arthritis (IA) and in healthy controls. Methods Autoantibody seroconversion was measured by serum ELISA in a longitudinal cohort of IA participants and healthy controls before and after COVID-19 mRNA-based immunization. Results Overall, there was a significantly lower incidence of ANA seroconversion in participants who did not contract COVID-19 prior to vaccination compared with those who been previously infected (7.4% vs 24.1%, P = 0.014). Incidence of de novo anti-CCP seroconversion in all participants was low at 4.9%. Autoantibody levels were typically of low titre, transient, and not associated with increase in IA flares. Conclusions In both health and inflammatory arthritis, the risk of autoantibody seroconversion is lower following mRNA-based immunization than following natural SARS-CoV-2 infection. Importantly, seroconversion does not correlate with self-reported IA disease flare risk, further supporting the encouragement of mRNA-based COVID-19 immunization in the IA population. [ABSTRACT FROM AUTHOR]